Yárnoz Irazábal, María Concepción

Loading...
Profile Picture

Email Address

Birth Date

Job Title

Last Name

Yárnoz Irazábal

First Name

María Concepción

person.page.departamento

Ciencias de la Salud

person.page.instituteName

person.page.observainves

person.page.upna

Name

Search Results

Now showing 1 - 1 of 1
  • PublicationOpen Access
    Prognostic relevance of preoperative immune, inflammatory, and nutritional biomarkers in patients undergoing gastrectomy for resectable gastric adenocarcinoma: an observational multicentre study
    (MDPI, 2024-06-11) Tur-Martínez, Jaume ; Rodríguez-Santiago, Joaquín; Osorio, Javier ; Miró, Mònica; Yárnoz Irazábal, María Concepción; Jofra, Mariona; Ferret, Georgina; Salvador-Roses, Helena; Fernández-Ananín, Sonia ; Clavell, Arantxa ; Luna, Alexis; Aldeano, Aurora; Olona, Carles; Hermoso, Judith; Güell-Farré, Mercè; Dal Cero, Mariagiulia; Gimeno, Marta; Pallarès, Natàlia; Pera, Manuel; Ciencias de la Salud; Osasun Zientziak
    Background: The aim of this study was to evaluate different preoperative immune, inflammatory, and nutritional scores and their best cut-off values as predictors of poorer overall survival (OS) and disease-free survival (DFS) in patients who underwent curative gastric cancer resection. Methods: This was a retrospective observational multicentre study based on data of the Spanish EURECCA Esophagogastric Cancer Registry. Time-dependent Youden index and log-rank test were used to obtain the best cut-offs of 18 preoperative biomarkers for OS and DFS. An adjusted Cox model with variables selected by bootstrapping was used to identify the best preoperative biomarkers, which were also analysed for every TNM stage. Results: High neutrophil-to-lymphocyte ratio (NLR), high monocyte systemic inflammation index (moSII), and low prognostic nutritional index (PNI) were identified as independent predictors of poor outcome: NLR > 5.91 (HR:1.73; 95%CI [1.23–2.43]), moSII >2027.12 (HR:2.26; 95%CI [1.36–3.78]), and PNI >40.31 (HR:0.75; 95%CI [0.58–0.96]) for 5-year OS and NLR > 6.81 (HR:1.75; 95%CI [1.24–2.45]), moSII > 2027.12 (HR:2.46; 95%CI [1.49–4.04]), and PNI > 40.31 (HR:0.77; 95%CI [0.60,0.97]) for 5-year DFS. These outcomes were maintained in the whole cohort for NLR and moSII (p < 0.05) but not in stage II and for PNI in all tumoral stages. The associations of NLR-PNI and moSII-PNI were also a relevant prognostic factor for OS. Conclusions: High NLR, high moSII (for stages I and III), and low PNI (regardless of tumour stage) were the most promising preoperative biomarkers to predict poor OS and DFS in gastric cancer patients treated with curative intent.